Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Empagliflozin/linagliptin/metformin extended release - Humanis Saglik Anonim Sirketi

Next Previous
Drug Profile

Empagliflozin/linagliptin/metformin extended release - Humanis Saglik Anonim Sirketi

Alternative Names: Linagliptin/empagliflozin/metformin extended release - Humanis Saglik Anonim Sirketi; Metformin/linagliptin/empagliflozin extended release - Humanis Saglik Anonim Sirketi

Latest Information Update: 17 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Humanis Saglik Anonim Sirketi
  • Class Alkynes; Amines; Antihyperglycaemics; Benzhydryl compounds; Biguanides; Cardiovascular therapies; Chlorinated hydrocarbons; Cyclic ethers; Eye disorder therapies; Glucosides; Heart failure therapies; Ketones; Piperidines; Purines; Quinazolines; Small molecules; Urologics
  • Mechanism of Action AMP activated protein kinase stimulants; Dipeptidyl peptidase 4 inhibitors; Gluconeogenesis inhibitors; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Type 2 diabetes mellitus

Most Recent Events

  • 15 Sep 2025 Humanis Saglık Anonim Sirketi completes phase-I clinical trials in Type 2 diabetes mellitus (In volunteers) in Jordan (PO) (NCT07213895)
  • 21 May 2025 Phase-I clinical trials in Type 2 diabetes mellitus (In volunteers) in Jordan (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top